{
    "nct_id": "NCT05808634",
    "official_title": "An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients With Advanced Adenocarcinoma",
    "inclusion_criteria": "* Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma\n* Age ≥ 18 years\n* Adequate renal function\n* Adequate liver function\n* Adequate hematological function\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have active autoimmune disease or a documented history of autoimmune disease.\n* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.",
    "miscellaneous_criteria": ""
}